Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.
Trial Parameters
Brief Summary
This study aims to investigate the safety and efficacy of the IL-22BP in patients with refractory malignant solid tumors.
Eligibility Criteria
Inclusion Criteria: 1. Male or female patients: aged ≥ 18 years old and ≤ 70 years old; 2. Patients with histopathologically confirmed, refractory to second-line treatment, advanced recurrent/metastatic malignant solid tumors and without standard clinical treatment regimens (such as patients with advanced soft tissue sarcoma, advanced head and neck squamous cell carcinoma, malignant melanoma, etc.); 3. Eastern Cooperative Oncology Group (ECOG) performance status score: 0 - 1; 4. Expected survival time ≥ 3 months; 5. More than 28 days since the last chemotherapy/radiotherapy/surgery; 6. More than 6 weeks since the last use of nitrosoureas or mitomycin C; 7. Main organ functions are in good condition; 8. Sign a written informed consent form. Exclusion Criteria: 1. Have participated in other drug clinical trials within 4 weeks; 2. The tumor is located close to major blood vessels or the trachea; 3. Patients with uncontrolled cardiac clinical symptoms or diseases, such as heart failure of